Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIERRA: Rituximab Immune Response in RA
NCT00282308Phase 2Completed
- Sponsor
- Genentech
- Start
- Jan 2006
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoint: Percentage of Patients With a Positive Immune Response to Tetanus Toxoid Adsorbed Booster Vaccine. Started Jan 2006; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00282308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282308.